Johnson & Johnson Zytiga Prostate Cancer Drug Approved in EU
Published: Sep 09, 2011
Johnson & Johnson's prostate cancer drug Zytiga has been approved in the European Union, paving the way for the launch of a new treatment for men whose disease has progressed after chemotherapy, the company said on Wednesday. The decision was expected after European regulators endorsed the treatment in July. J&J's Janssen unit has European rights for the product. Zytiga, or abiraterone, works by blocking the synthesis of testosterone, which can fuel cancer growth.